Rare disease drug development often depends on speed, flexibility, and regulatory clarity. But when the FDA’s approach shifts, the impact can be huge for biotech companies, investors, physicians, and patients waiting for new treatment options.
In this episode, we break down the FDA’s evolving stance on rare disease approvals, why regulatory expectations can suddenly change, and what this uncertainty means for the future of orphan drug development. We also look at how companies may need to rethink trial design, evidence standards, and investor messaging in a more cautious approval environment.
Podcast: Play in new window | Download
